Literature DB >> 31562490

'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Dimitrios C Mastellos1, Anna M Blom2, E Sander Connolly3, Mohamed R Daha4, Brian V Geisbrecht5, Berhane Ghebrehiwet6, Piet Gros7, George Hajishengallis8, V Michael Holers9, Markus Huber-Lang10, Taroh Kinoshita11, Tom E Mollnes12,13,14, Robert A Montgomery15, B Paul Morgan16, Bo Nilsson17, Ruben Pio18, Daniel Ricklin19, Antonio M Risitano20, Ronald P Taylor21, Alberto Mantovani22, John P A Ioannidis23, John D Lambris24.   

Abstract

Entities:  

Year:  2019        PMID: 31562490      PMCID: PMC7368001          DOI: 10.1038/s41590-019-0503-1

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  1 in total

1.  Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?

Authors:  T Kanni; O Zenker; M Habel; N Riedemann; E J Giamarellos-Bourboulis
Journal:  Br J Dermatol       Date:  2018-05-10       Impact factor: 9.302

  1 in total
  2 in total

Review 1.  Compstatins: the dawn of clinical C3-targeted complement inhibition.

Authors:  Christina Lamers; Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Trends Pharmacol Sci       Date:  2022-01-25       Impact factor: 17.638

Review 2.  Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.

Authors:  Marion Ort; Jasper Dingemanse; John van den Anker; Priska Kaufmann
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.